drugset / Trial / NCT00925106

Pharmacokinetics Of Celecoxib Test Formulations

NCT00925106

Phase 1 Completed 16 enrolled Viatris Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.

Timeline

Start
2009-07
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 150 mg
Comparator Celecoxib Other / unclassified 200 mg

Indications

No indication recorded.